Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Pulmonary Hypertension in Obesity
NCT03349775Phase 1Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of liquid metformin (Aspargo Labs) in pulmonary hypertension (PH) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Pulmonary Vascular Hemodynamics at Rest at 3 months and Pulmonary Vascular Hemodynamics during Exercise at 3 months. Started Nov 2017; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT03349775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349775.